

# 2025 PanCAN Scientific Summit

## SCIENTIFIC SESSIONS: Poster Session 2

*The Square, Lobby Level*

*Sunday, September 28, 7:30 – 8:10 a.m.; 12:25 – 1:20 p.m.*

### 1. Astellas

**Affiliation:** Industry Champion

**Topic:** The Emotional Journey of Metastatic Pancreatic Cancer: Key Findings from U.S. Market Research

### 2. Immuneering

**Affiliation:** Industry Champion

**Topic:** Atebimetinib + mGnP: Overall Survival and Safety Data in First Line Pancreatic Cancer Patients

### 3. Ipsen

**Affiliation:** Industry Champion

**Topic:** Characteristics of long-term survivors and impact of dose adjustments in first-line NALIRIFOX treatment for metastatic pancreatic ductal adenocarcinoma: *post hoc* analyses of NAPOLI 3

### 4. Novocure

**Affiliation:** Industry Champion

**Topic:** PANOVA-3: pain and quality of life (QoL) outcomes with Tumor Treating Fields (TTFields) therapy in patients with locally advanced pancreatic adenocarcinoma (LA-PAC)

### 5. Partner Therapeutics

**Affiliation:** Industry Champion

**Topic:** Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer: Pancreatic Cancer Cohort

### 6. Revolution Medicines

**Affiliation:** Industry Champion

**Topic:** Daraxonrasib, a RAS(ON) multi-selective inhibitor, exhibits potent antitumor activity and combinatorial benefit with standard of care chemotherapy and with anti-PD-1 in preclinical models of KRAS G12R PDAC